Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
SCY‐078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species. This was a sequential, single‐center, open‐label phase 1 study to assess the drug‐drug interaction potential between SCY‐078 and tacrolimus during concomitant administration in healthy subjects. In cohort 1, period 1, subjects received a single oral dose of tacrolimus 2 mg in the fasted state. In period 2 after a ≥15 day washout, subjects received a single loading dose of SCY‐078 1250 mg on day 1 followed by maintenance doses of SCY‐780 750 mg on days 2 through 8. On day 3 of period 2, subjects also received a single dose of tacrolimus 2 mg concurrent with SCY‐078. In cohort 2, subjects received a loading dose of SCY‐078 1250 mg on day 1 followed by maintenance doses of SCY‐780 750 mg on days 2 and 3. Pharmacokinetic (PK) parameters were compared to assess both the impact of steady‐state SCY‐078 on tacrolimus and the impact of tacrolimus on the PK of steady‐state SCY‐078. The concurrent coadministration of tacrolimus and SCY‐078 had no effect on the maximum blood levels of tacrolimus, as evidenced by no change in maximum concentration of drug in blood plasma and a 1.4‐fold increase in total area under the plasma drug concentration–time curve. The concurrent coadministration of tacrolimus and SCY‐078 resulted in a weaker interaction than typically observed with the azole class of antifungals. The current data indicate that an initial dose adjustment for tacrolimus may not be warranted when combined with SCY‐078, as the modest increase in exposure is less than the therapeutic window, although tacrolimus monitoring, as with addition of any new medication, is recommended. These results support the coadministration of SCY‐078 and tacrolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
SCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Self-citation
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“These findings support the coadministration of ibrexafungerp and tacrolimus without the need for an initial dose adjustment for tacrolimus [119].”
ResultIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Ibrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
Self-citation
Metadata
- Authors
- Wring, S., Murphy, G., Atiee, G., Corr, C., Hyman, M., Willett, M., & Angulo, D.
- Venue
- Clinical Pharmacology in Drug Development
- Publisher
- Wiley
- Published
- 2018-06-27
- Volume
- 8
- Issue
- 1
- Pages
- 60-69
- ISSN
- 2160-763X (ISSN-L)
- 2160-7648
- OpenAlex
- W2809686644
- Cited by
- 45
- References
- 2
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. https://app.cochat.ai/papers/10.1002/cpdd.588
- The paper
- Wring, S., Murphy, G., Atiee, G., Corr, C., Hyman, M., Willett, M., & Angulo, D. (2019). Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.